In contrast, a meta-analysis evaluated 299 melanoma cases from five studies for expression levels of CD133 and reported low power to detect a significant association between CD133 expression and melanoma progression [153], suggesting that CD133 might not be an appropriate biomarker in identifying melanoma CSCs. This evidence concerns the gene PROM1 and melanoma.